Case-control genome-wide association (CC-GWAS) studies might provide valuable clues to the underlying pathophysiologic mechanisms of complex diseases, such as neurodegenerative disease, cancer. A commonly overlooked complication is that multiple distinct disease states might present with the same set of symptoms and hence share a clinical diagnosis. These disease states can only be distinguished in a biomarker evaluation that might not be feasible on the whole set of cases in the large number of samples that are typically needed for CC-GWAS. Instead, the biomarkers are measured on a subset of cases. Or an external reliability study estimates frequencies of the disease states of interest within the clinically diagnosed set of cases. These frequencies often vary by the genetic and/or non-genetic variables. We derive a simple approximation that relates the genetic effect estimates obtained in a logistic regression model with the clinical diagnosis as an outcome variable to the estimates in the relationship to the true disease state of interest. We performed simulation studies to assess accuracy of the approximation that we've derived. We next applied the derived approximation to the analysis of the genetic basis of innate immune system of Alzheimer's disease.
INTRODUCTION
Case-control genome-wide analyses scan (CC-GWAS) is a tool that is widely used to elucidate the genetic basis of complex diseases. A common complication is that multiple distinct disease states share the observed symptoms and hence the clinical diagnosis.
Frequencies of the disease states within the clinical diagnosis often vary by the key variables. If the disease states have distinct genetic basses, the analyses with a clinical diagnosis as an outcome variable might be substantially biased (Carroll et al, 2006) .
The specific example that motivated this study is the analyses of the genetic susceptibility to Alzheimer's disease (AD). The clinical diagnosis of AD is typically made based on a set of descriptive criteria and only a small subset of cases receives positron emission tomography (PET) to evaluate for amyloid positivity, what is a requirement for the true, or pathologically defined, AD. Recent biomarker studies (Salloway and Sperling, 2015) estimate that 36% of ApoE We are interested to examine the role of the genetic variants serving the innate immune system in susceptibility to AD, i.e. the AD symptoms underlined by the amyloid deposition. The usual analyses define the outcome variable in a regression analysis to be the clinical diagnosis. We, however, recognize heterogeneity of the clinical diagnosis where the underlying disease state separates the cases into a subset with amyloid- (Kullback, 1959) .
Our paper is organized as follows. First, in the Material and Methods section we present the setting, notation, and the proposed approximation for various models. Next, in the Simulation Experiments section we describe the empirical studies that are conducted to compare the resulting performance of the approximation that we derived relative to the average observed across many simulated datasets. We then compare the estimates in a practical setting of an Alzheimer's disease study that aims to investigate the genetic basis of innate immune system in the relationship to the AD symptoms underlined by amyloid pathology. We conclude our paper with brief Discussion. reliably estimated in an external reliability study. We define the clinical-pathological diagnosis relationship using
MATERIALS AND METHODS

We
what is a frequency of the disease state of interest within the clinically diagnosed set and the frequency varies by ܺ . In the context of AD study,
. We define the probabilities of the clinical diagnosis in the population to be
. Similarly, we let frequencies of the true pathologic state in the population to be
Derivations provided in Appendix A1 show that
From (4a) and (4b), we derive that
Appendix A3 describes how to obtain
assuming estimates of
are available from the usual logistic regression and reliable estimates of 
while the model used is
Derivations provided in Appendix A2 show that Remarks:
, then
Model 2, equation (8b). If
ߚ ீ ൌ ߙ ீ ൌ 0 , then ߛ ீ ൌ 0 .
Model 2, equation (8c). If
4. Remarks 1-3 describe when the usual logistic regression models with the clinical diagnosis as an outcome variable correctly estimate the null effect.
5. The equations that we derived apply to several possible likelihood functions. For example, parameter estimates in Model 3 can be estimated based on the usual logistic regression model, i.e. the probability of the form
or in a pseudolikelihood (Spinka et al, 2005; Lobach et al, 2018 )
is an imaginary indicator of being selected into the study. All the derivations apply to both models.
SIMULATION STUDIES
False positive rate We first perform a series of simulation experiments to examine a false positive rate in the estimates of ߚ ீ when the data are simulated from model (1)- (2), but the parameter estimates are obtained from model (3). We define the false positive rate to be the fraction of p-values0.05 across 10,000 simulated datasets in the usual logistic regression analyses as an outcome variable, i.e. (3), when in fact
. We simulate the data using model (1) with coefficients
We next estimate parameters using model (3). Table   1 presents false positive rates in datasets with
When the genetic effect is not associated with the clinical diagnosis, the false positive rate is nominal, i.e. is nearly 0.05. When
increases, the false positive rate gets inflated, e.g.
, the false positive rate is 0.72. Increase in sample size did not result in decrease of the false positive rate.
Approximation vs. empirical estimates We next perform a series of simulation
experiments to assess the magnitude of bias and the approximation to the relationships that we've derived. First, we estimate the bias empirically as the average across 500 simulated datasets where the data are simulated using the true model (1)- (2), (5)- (6) (7) and (A5). We then compare these averages to the approximations that we've derived.
We simulate genotype ‫,)ܩ(‬ age ‫,)ܣ(‬ sex (ܵ), ApoE We then simulated the clinical diagnosis status ‫ܦ‬ according to the models (3), (7) and (A5) and the true disease states ‫ܦ‬ according to model (1)- (2), (5)- (6), (A3)-(A4). In all simulations we let
Model 1 We fist simulate the data using model (1)- (2) and estimate parameters in the logistic model (3). We set
and simulate datasets with 3,000 cases and 3,000 controls. Model 2 We next generate data using models (5)- (6) but estimate parameters using model (7). We let
and generate datasets with 3,000 cases and 3,000 controls. Approximations and the empirical estimates for ߛ ீ
shown in Table 3 demonstrate that the approximation (8b) is accurate relative to the empirical estimates. The empirical estimate of
is 2.09, while the approximation is 2.08.
Model 3
We next simulate data using models (A3)-(A4) and estimate parameters using model (A5), with the approximation derived in (A6a-c). are not associated with the nuisance disease status (ߙ
). We simulate the clinical diagnosis and disease states with coefficients Setting 3. We next consider a setting when with the nuisance disease the genotype is
), and no interaction
We next change the parameters for the nuisance state to be
and all other parameters ) and there is significant
). We next change the parameters for the nuisance state to be ) and the
. Shown along the x-axis are values of . We note that these frequencies are similar to those in context of Alzheimer's disease.
ROLE OF THE GENETIC VARIANTS SERVING INNATE IMMUNE SYSTEM IN SUSCEPTIBILITY TO ALZHEIMER's DISEASE
We apply the usual logistic analyses with the clinical diagnosis as an outcome variable to a dataset collected as part of the Alzheimer's Disease Genetics Consortium. We next apply the approximations (7)- (10) and (11)- (14) to see how the genetic estimates change when presence of the nuisance disease state is recognized.
We mapped Illumina Human 660K markers onto human chromosomes using NCBI (7); and the corresponding models (1-2) and (5-6) that recognize presence of the nuisance disease state. In the univariable setting the empirical bias is estimated as the difference between the main effect estimates obtained in model (3) and model (1-2), and the approximation to the bias is estimated as derived in (4b). In the multivariable setting, the empirical bias is the difference between main effect estimates obtained in model (7) and (5-6), and the approximation is as derived in (8b). Table 4 are 16 estimates with p-value<0.05 after the Benjamini-Hochberg multiple testing adjustment in a univariable model (3) and then added are 13 SNPs with p-value <0.05 in a univariable model (1-2). Across all these SNPs, the approximation was accurate relative to the empirical bias.
First shown in
DISCUSSION
We've examined a situation when multiple disease states share observed symptoms and hence the clinical diagnosis. Both theoretically and in extensive simulation studies we observed that the magnitude of bias can be substantial in situations when frequency of the nuisance disease state within the clinically diagnosed set varies by the key variables. We derived a simple and general approximation to the relationship between the genetic effect estimates that use the clinical diagnosis as an outcome variable and the estimates that recognize presence of the nuisance disease state.
While the effect of misclassification of the disease status has been examined Simulation studies that we conducted showed that when presence of the nuisance disease is ignored, the genetic effect estimates can be biased in either direction. These biases can be substantial in magnitude leading to false positive and false negative results.
While our study is motivated by the setting of Alzheimer's disease, the results are readily applicable for other complex diseases. For example, Manchia el al (2013) examined the effect of heterogeneity, i.e. presence of non-cases, in the context of diabetes and showed that ignoring the heterogeneity leads to reduced statistical power to detect an association and also reduced the estimated risks attributable to susceptibility alleles.
The approximation that we've derived is widely applicable in other areas of research where the diagnosis is heterogeneous. For example, when disease states correspond to subtypes of a complex disease. We also see the application to the analyses of Electronic Health Records, where the disease status might be subject to exposuredependent differential misclassification (Chen et al, 2017) .
Samples from the National Cell Repository for Alzheimer's Disease (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible;
Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689-01) and the data are generated from (1)-(2). We let and approximation (4b). The data are simulated from models (1)- (2) and is estimated using model (3). Empirical estimates are the averages across 500 datasets with 3,000 cases and 3,000 controls. We let and approximation (8b). The data are simulated from models (5)- (6) and is estimated using model (7). Empirical estimates are the averages across 500 datasets with 3,000 cases and 3,000 controls. We let (7); and the corresponding models (1-2) and (5-6) that recognize presence of the nuisance disease state. In the univariable setting the empirical bias is estimated as the difference between the main effect estimates obtained in model (3) and model (1-2), and the approximation is as derived in (4b). In the multivariable model, the empirical bias is the difference between main effect estimates obtained in model (7) and (5-6), and the approximation is as derived in (8b).
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